NFGH
ABCL icon

Nan Fung Group Holdings’s AbCellera Biologics ABCL Stock Holding History

Nan Fung Group Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,971
Closed -$151K – 39
2024
Q2 		$151K Hold
50,971
– – 0.16% 40
2024
Q1 		$231K Buy
50,971
+38,450
+307% +$196K 0.21% 39
2023
Q4 		$71.5K Hold
12,521
– – 0.04% 36
2023
Q3 		$57.6K Hold
12,521
– – 0.05% 36
2023
Q2 		$80.9K Hold
12,521
– – 0.05% 41
2023
Q1 		$94.4K Hold
12,521
– – 0.06% 42
2022
Q4 		$127K Hold
12,521
– – 0.09% 38
2022
Q3 		$124K Hold
12,521
– – 0.08% 36
2022
Q2 		$133K Hold
12,521
– – 0.09% 37
2022
Q1 		$122K Sell
12,521
-659
-5% -$6.24K 0.06% 41
2021
Q4 		$188K Buy
+13,180
New +$200K 0.06% 49

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nan Fung Group Holdings's ABCL Position: Q3 2024 in Review

Nan Fung Group Holdings sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 50,971 shares — an estimated $151K sold.

Nan Fung Group Holdings first reported a position in ABCL in Q4 2021 and held it in 11 quarters. The position peaked at $231K in Q1 2024. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Nan Fung Group Holdings reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Nan Fung Group Holdings sold 50,971 AbCellera Biologics shares in Q3 2024, an estimated $151K.
  • Nan Fung Group Holdings first reported a position in AbCellera Biologics in Q4 2021 and held it in 11 quarters.
  • Nan Fung Group Holdings's AbCellera Biologics position peaked at $231K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Nan Fung Group Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.